Richard Shea
Direktor/Vorstandsmitglied bei SYNLOGIC, INC.
Vermögen: 930 $ am 30.04.2024
Aktive Positionen von Richard Shea
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SYNLOGIC, INC. | Direktor/Vorstandsmitglied | 28.08.2017 | - |
Independent Dir/Board Member | 28.08.2017 | - | |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Richard Shea
Ehemalige bekannte Positionen von Richard Shea
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SYNDAX PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | - | 13.07.2020 |
Direktor/Vorstandsmitglied | 23.01.2014 | 13.02.2017 | |
Finanzdirektor/CFO | 13.02.2017 | 13.07.2020 | |
Independent Dir/Board Member | 23.01.2014 | 13.02.2017 | |
Treasurer | 13.02.2017 | 13.07.2020 | |
MOMENTA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.07.2007 | 10.03.2015 |
Finanzdirektor/CFO | 01.10.2003 | 01.12.2016 | |
Variagenics, Inc.
Variagenics, Inc. Miscellaneous Commercial ServicesCommercial Services Variagenics, Inc. develops molecular diagnostic tests by identifying genetic markers associated with response to cancer therapies, with the goal of optimizing patient care through both biopharmaceutical collaborations and its own internal research programs | Geschäftsführer | 01.02.1999 | 01.04.2003 |
Finanzdirektor/CFO | 01.02.1999 | 01.04.2003 | |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Finanzdirektor/CFO | 01.01.1992 | 01.01.1999 |
Ausbildung von Richard Shea
Boston University | Masters Business Admin |
Princeton University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Israel | 2 |
Operativ
Director/Board Member | 4 |
Director of Finance/CFO | 4 |
Independent Dir/Board Member | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
SYNDAX PHARMACEUTICALS, INC. | Health Technology |
SYNLOGIC, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Variagenics, Inc.
Variagenics, Inc. Miscellaneous Commercial ServicesCommercial Services Variagenics, Inc. develops molecular diagnostic tests by identifying genetic markers associated with response to cancer therapies, with the goal of optimizing patient care through both biopharmaceutical collaborations and its own internal research programs | Commercial Services |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Richard Shea
- Erfahrung